Busulphan
Childhood Acute Myelomonocytic Leukemia (M4)
National Cancer Institute (NCI)Phase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Childhood Acute Myelomonocytic Leukemia (M4) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
THIOGUANINE ANHYDROUS Children's Oncology Group | Phase 3 | BB |
Romidepsin National Cancer Institute (NCI) | Phase 3 | BB |
PEGASPARGASE Children's Oncology Group | Phase 3 | BB |
ASPARAGINASE Children's Oncology Group | Phase 3 | BB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) Children's Oncology Group | Phase 3 | BB |
METHOTREXATE National Cancer Institute (NCI) | Phase 3 | BB |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 3 | B |
Solu-Cortef National Cancer Institute (NCI) | Phase 3 | B |
Same molecule, other indications
Busulphan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →